x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Proactive - Interviews for investors

Welcome to the Proactive podcast channel – the destination for breaking news on growth companies and up to the minute market coverage. Here we plug you into what’s new and exciting in the world of business.

business investing

All Episodes

00:05:15

Light Science Technologies CEO discusses strong...

Proactive - Interviews for investors ·

2024/09/10

Light Science Technologies Holdings PLC (AIM:LST) CEO Simon Deacon speaks with Proactive's Stephen Gunnion about the company's recent successes in the Passive Fire Protection (PFP) division, announcing the completion of new contracts worth £145,000. These projects, located in London and Liverpool, contribute to a total of £2 million in work expected to be completed within the financial year. Deacon highlighted the efficiency of their injector-clad product, which plays a crucial role in preventing

en

00:08:53

Futura Medical achieves milestone with first profit...

Proactive - Interviews for investors ·

2024/09/10

Futura Medical PLC (AIM:FUM, OTC:FAMDF) CEO James Barder joined Proactive's Stephen Gunnion with details of company’s latest financial results and future outlook. Barder highlighted that Futura Medical has increased guidance on both profit and revenue for the remainder of the year. Its flagship product, Eroxon, a clinically proven treatment for erectile dysfunction, has now launched in ten countries, with its most recent debut in Mexico. Barder emphasised the significance of Eroxon entering

en

00:05:15

Finseta CEO discusses 40% H1 revenue growth following...

Proactive - Interviews for investors ·

2024/09/10

Finseta plc (AIM:FIN) CEO James Hickman takes Proactive's Stephen Gunnion through the company’s strong financial performance for H1 2024, marking a 40% revenue increase after exiting its white-label business. Hickman emphasised that Finseta’s direct-to-market strategy boosted margins to 65.7%, highlighting its scalability and cost-efficiency. He also discussed the significant 29% rise in average transaction value, which came from the company's strategic focus on deepening customer relationships

en

00:12:30

Blackbird ends first half well positioned to grow...

Proactive - Interviews for investors ·

2024/09/10

Blackbird PLC (AIM:BIRD, OTC:BBRDF) CEO Ian McDonough, chair Anne de Kerckhove and non-executive director Youri Hazanov joined Proactive's Stephen Gunnion to discuss the strong progress that the company has made with its flagship elevate.io platform and new and recent board appointments. Unveiling the company's interim results, McDonough highlighted the company's involvement in high-profile events like the Paris Summer Games while acknowledging a 30% drop in top-line growth due to non-renewed

en

00:04:30

John Shaw discusses Itaconix’s half-year results &...

Proactive - Interviews for investors ·

2024/09/10

Itaconix CEO John Shaw joined Steve Darling from Proactive to provide an update on the company’s recent performance and initiatives, with a particular focus on its evolving digital marketing strategy. Shaw expressed optimism about Itaconix’s trajectory, reflecting on both the successes and challenges faced in the first half of 2024. He noted that while the company’s restructuring efforts resulted in lower revenues, they successfully improved gross profit margins, which are now nearing their target

en

00:07:53

hVIVO CEO discusses record H1 revenue and strategic...

Proactive - Interviews for investors ·

2024/09/10

hVIVO PLC (AIM:HVO) chief executive Yamin (Mo) Khan speaks with Proactive's Stephen Gunnion about the company's achievements in the first half of 2024, including a 31% increase in revenue, reaching £35.6 million. Khan highlighted the company's record EBITDA of £8.7 million, reflecting a 68% year-on-year growth. He attributed these successes to the opening of the world’s largest human challenge trial facility in Canary Wharf, which includes 50 beds for CL3 level pathogen trials. Khan also spoke

en

00:08:27

Tissue Regenix reports strong first half as it...

Proactive - Interviews for investors ·

2024/09/10

Tissue Regenix Group PLC (AIM:TRX) CEO Danny Lee and CFO David Cocke take Proactive's Stephen Gunnion through company’s significant financial progress and strategic growth pillars. Cocke highlighted a strong first half of 2024, with revenues increasing by 16% to $16.4 million. This marks the eighth consecutive growth period, with the gross profit margin rising to 53%, and EBITDA more than doubling to $1.1 million. Notably, the company achieved its first pre-tax profit, a milestone in its

en

00:07:55

Electric Guitar CEO discusses strong progress since...

Proactive - Interviews for investors ·

2024/09/10

Electric Guitar PLC (AIM:ELEG) CEO John Regan discusses the company's development over the last four months since its market launch in May. During the interview, Regan detailed the recent restructuring efforts, including the addition of sales and marketing personnel and product optimisation, which has significantly reduced deployment times for their solutions. Regan touched on a new agreement with Jewson, one of the UK's prominent suppliers of sustainable building materials. The collaboration will

en

00:05:07

North Bay Resources begins gold shipments from Fran...

Proactive - Interviews for investors ·

2024/09/09

North Bay Resources CEO Jared Lazerson joined Steve Darling from Proactive to announce that the company has initiated gold ore shipments from its Fran Gold Project to the Bishop Gold Mill. A four-man crew has been deployed to the site, with the first tractor trailers set to arrive next week. The initial shipment will consist of 44 tons of surface material, manually loaded into one metric tonne super-sacks for transport on flat-bed tractor trailers. Lazerson shared that the target material has been

en

00:05:42

Nanoviricides investigates NV-387 for MPOX treatment...

Proactive - Interviews for investors ·

2024/09/09

Nanoviricides CEO Dr Anil Diwan joined Steve Darling from Proactive to discuss the company's exploration of using its antiviral candidate, NV-387, for the treatment of MPOX patients under the World Health Organization's (WHO) MEURI protocol. This comes in response to the 2024 MPOX outbreak, which is rapidly spreading across more than ten African countries, with additional cases reported in Thailand and Sweden. Dr. Diwan explained that NV-387 has already completed Phase I clinical trials for safety

en

00:05:45

Alvopetro Energy CEO discusses breakthrough natural...

Proactive - Interviews for investors ·

2024/09/09

Alvopetro Energy CEO Corey Ruttan joined Steve Darling from Proactive to discuss the company’s impressive achievements and future outlook in Brazil's natural gas sector. Ruttan highlighted the pivotal moment on July 5, 2020, when Alvopetro became the first independent company to deliver sales-specified natural gas to the local market, breaking the long-standing monopoly held by the state oil company, Petrobras. Operating in the Reconcavo Basin in northeast Brazil, Alvopetro supplies natural gas to

en

00:05:10

First Phosphate secures facility lease for 10,000...

Proactive - Interviews for investors ·

2024/09/09

First Phosphate's CEO, John Passalacqua, shared exciting news with Proactive's Steve Darling, announcing that the company has successfully secured a lease for a state-of-the-art 10,000 tonne per annum iron phosphate precursor plant in Saguenay, Quebec. This facility will play a critical role in the production of cathode active material, a key component for lithium iron phosphate (LFP) batteries, as demand for efficient and sustainable energy storage solutions continues to rise. Passalacqua

en

00:03:40

Oncimmune on track for a profit in 2025 as it...

Proactive - Interviews for investors ·

2024/09/09

Oncimmune Holdings PLC (AIM:ONC) CEO Martin Gouldstone takes Proactive's Stephen Gunnion through the company's 2024 trading update and its outlook for FY25. Gouldstone highlighted key achievements, including signing new contracts with top pharmaceutical companies and introducing innovative bioinformatics capabilities. These developments, coupled with the company's omics analysis contract, underscore Oncimmune's growing commercial traction. Gouldstone also confirmed that Oncimmune's revenues for

en

00:06:17

Frontier IP: The Vaccine Group CEO discusses £1mln in...

Proactive - Interviews for investors ·

2024/09/09

Frontier IP Group PLC (AIM:FIPP) portfolio company The Vaccine Group (TVG) has been awarded more than £1 million in funding by the UK Government to develop a vaccine for Streptococcus suis. TVG CEO Jeremy Salt spoke to Proactive's Stephen Gunnion about the company's work on a vaccine for the global bacterial disease affecting pig populations. He explained the challenges posed by the strain variations of this bacteria, the reliance on antibiotics, and the current inefficiencies of available

en

00:04:08

Andrada Mining's game-changing lithium deal with SQM

Proactive - Interviews for investors ·

2024/09/09

Andrada Mining Ltd (AIM:ATM, OTC:AFTTF) CEO Anthony Viljoen talked with Proactive about the company's major new partnership with Chile-based SQM, one of the world's largest lithium chemicals producers, to develop its Lithium Ridge prospect at Uis in Namibia. Viljoen described the deal as the largest in Andrada's history, emphasising the significance of collaborating with one of the world's top lithium producers. The partnership will bring both financial and technical support, rapidly advancing

en

00:06:43

Sunda Energy CEO on H1 milestones, new strategy and...

Proactive - Interviews for investors ·

2024/09/09

Sunda Energy PLC (AIM:SNDA) CEO Andy Butler talked with Proactive about the company’s recent progress and strategic shift following the release of its interim results. Butler outlined key developments, including Sunda Energy’s refocused strategy towards Southeast Asia and its core assets in Timor-Leste. He discussed the company’s milestone achievements, such as increased participation from Timor Gap and its alignment with regional governments. “We see gas markets that are very strong, with

en

00:05:24

Ilika's Goliath batteries exceed safety test...

Proactive - Interviews for investors ·

2024/09/09

Ilika Plc CEO Graeme Purdy takes Proactive's Stephen Gunnion through the recent successful safety test results of the company's Goliath solid-state battery prototypes. Purdy highlighted that the independent tests, conducted under the SafeBatt program, exceeded expectations, demonstrating the robust performance of Ilika's batteries under extreme conditions. The tests revealed no thermal runaway in Ilika's Goliath prototypes, contrasting with explosions seen in standard lithium-ion cells, making

en

00:02:08

European Green Transition's Olserum drill program...

Proactive - Interviews for investors ·

2024/09/09

European Green Transition PLC CEO Aiden Lavelle discusses the company’s recently completed drill program at the Olserum Rare Earth Project with Proactive's Stephen Gunnion. Lavelle shared that the program, consisting of 1,500 meters of drilling across 13 holes, finished ahead of schedule and under budget. Ten holes were drilled at the Djupedal prospect, while the remaining three targeted the Olserum West prospect. Lavelle highlighted that the company is optimistic about the visual results from

en

00:06:46

Zephyr Energy CEO on successful State 36-2R well...

Proactive - Interviews for investors ·

2024/09/09

Zephyr Energy PLC (AIM:ZPHR, OTCQB:ZPHRF) CEO Colin Harrington joined Steve Darling from Proactive to provide an operational update on the State 36-2R LNW-CC well at the company’s flagship project in the Paradox Basin, Utah. The company has successfully completed the second phase of the production test, with the acidization operation effectively removing near-wellbore formation damage. This resulted in significantly enhanced reservoir deliverability and improved permeability near the wellbore

en

00:11:13

Immunic says first patient enrolled in...

Proactive - Interviews for investors ·

2024/09/09

Immunic Inc chief medical officer Dr Andreas Muehler speaks to Proactive's Stephen Gunnion about the start of an investigator-sponsored Phase 2 clinical trial focused on treating Post COVID Syndrome (PCS) with its lead compound, vidofludimus calcium. This drug is currently in Phase 3 trials for multiple sclerosis and has shown potential as a broad-spectrum antiviral. Muehler explained that the trial, initiated by a group of German investigators, aims to investigate the role of viral reactivation

en

4,496 results

Similar Podcasts

TaxTalent.com The Golden Rule Podcast

Adam Golden

TaxTalent.com Podcast

Tony Santiago

Handelsblatt Crime - spannende Streitfälle der deutschen Wirtschaft

Ina Karabasz, Solveig Gode, Sönke Iwersen

Deffner und Zschäpitz – Der Wirtschafts-Talk von WELT

WELT

Black Box - La scatola nera della finanza

Guido Brera e Gian Luca Comandini -...